MMedication Read More Diversify With These Health ETFsMarch 23, 2026 The FDA recently approved higher-dose version of Novo Nordisk’s NVO obesity drug Wegovy, further expanding the drug giant’s footprint in…
MMedication Read More Ozempic Goes Generic —But Not in the USMarch 23, 2026 A drug that helped turn Novo Nordisk into Europe’s most valuable company is about to lose its…
MMedication Read More Coming Soon: ‘Wegovy HD’March 21, 2026 Federal regulators on Thursday approved a new higher-dose version of the blockbuster obesity drug Wegovy that may…
HHealth Read More Semaglutide Falls Short in Alzheimer’s Phase 3 TrialsMarch 21, 2026 Phase 3 trials show oral semaglutide failed to slow early Alzheimer’s progression, potentially limiting its expansion beyond metabolic…
MMedication Read More FDA sends letter to Novo Nordisk over potential GLP-1 side effectsMarch 14, 2026 The U.S. Food and Drug Administration sent a warning letter this month to Novo Nordisk, the maker of…
MMedication Read More FDA sends letter to Novo Nordisk over potential GLP-1 side effectsMarch 13, 2026 The U.S. Food and Drug Administration sent a warning letter this month to Novo Nordisk, the maker of…
HHealthcare Read More WHO Foundation and Novo Nordisk Expand Collaboration to Provide Financial Support towards strengthening health systems for Cardio-Renal-Metabolic DiseasesMarch 12, 2026 GENEVA, March 11, 2026 /PRNewswire/ — The WHO Foundation today announced an expanded collaboration with Novo Nordisk to support…
MMedication Read More Weight-loss wegovy jab may carry greater risk of sudden sight loss, study finds – The Irish TimesMarch 11, 2026 Patients taking Wegovy have nearly five times the risk of sudden sight loss compared with those on Ozempic,…
MMedication Read More Hims & Hers abandons plan for cheaper Wegovy knockoff after FDA warningMarch 11, 2026 Telehealth company Hims & Hers dropped its plan to offer a knockoff version of the weight-loss pill Wegovy…
MMedication Read More Hims & Hers will sell real Ozempic in deal with Novo NordiskMarch 11, 2026 Hims & Hers and the Danish pharma giant Novo Nordisk have ended a bitter legal feud that will…
MMedication Read More FDA warns Novo Nordisk over unreported potential Ozempic side effectsMarch 10, 2026 Novo Nordisk, the pharmaceutical company behind Ozempic, has received a warning letter from the U.S. Food and Drug…
MMedication Read More The era of $199 copycat weight loss drugs is ending — and it could cost patientsMarch 10, 2026 After two splashy Super Bowl commercials focused on making weight loss medication more accessible, Hims & Hers will…